Ponazuril

Ponazuril
Clinical data
Trade names	Marquis
Other names	ACD855; ACD-855
AHFS/Drugs.com	FDA Professional Drug Information
Routes of; administration	Oral
ATCvet code	QP51BC04 (WHO) ;
Legal status
Legal status	US: ℞-only; Veterinary use only;
Identifiers
	IUPAC name 1-Methyl-3-[3-methyl-4-[4-(trifluoromethylsulfonyl)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione;
CAS Number	69004-04-2 ;
PubChem CID	3050408;
ChemSpider	2312474 ;
UNII	JPW84AS66U;
CompTox Dashboard (EPA)	DTXSID7048958 ;
ECHA InfoCard	100.157.907
Chemical and physical data
Formula	C18H14F3N3O6S
Molar mass	457.38 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC(=C1)N2C(=O)NC(=O)N(C2=O)C)OC3=CC=C(C=C3)S(=O)(=O)C(F)(F)F;
	InChI InChI=1S/C18H14F3N3O6S/c1-10-9-11(24-16(26)22-15(25)23(2)17(24)27)3-8-14(10)30-12-4-6-13(7-5-12)31(28,29)18(19,20)21/h3-9H,1-2H3,(H,22,25,26) ; Key:VBUNOIXRZNJNAD-UHFFFAOYSA-N ;
	(what is this?) (verify)

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Ponazuril (INN), sold by Merial, Inc.,^[1] now part of Boehringer Ingelheim,^[2] under the trade name Marquis® (15% w/w ponazuril), is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by coccidia Sarcocystis neurona.^[3]^[4] Veterinarians have been preparing a formulary version of the medication for use in small animals such as cats, dogs, and rabbits against coccidia as an intestinal parasite. Coccidia treatment in small animals is far shorter than treatment for EPM.^{[citation needed]} Along with its analogue ACD856, ponazuril (also known as ACD855) is a positive allosteric modulator of the tropomyosin receptor kinases TrkA and TrkB.^[5]

References

^ "Merial Acquires LEGEND® and MARQUIS®". Boehringer Ingelheim. Retrieved 2018-04-30.
^ "Sanofi and Boehringer Ingelheim confirm Closing of business swap | www.boehringer-ingelheim.com". boehringer-ingelheim.com. Retrieved 2018-04-30.
^ "Marquis". Drugs.com.
^ Mackay RJ, Tanhauser ST, Gillis KD, Mayhew IG, Kennedy TJ (March 2008). "Effect of intermittent oral administration of ponazuril on experimental Sarcocystis neurona infection of horses". American Journal of Veterinary Research. 69 (3): 396–402. doi:10.2460/ajvr.69.3.396. PMID 18312139.
^ Dahlström M, Madjid N, Nordvall G, Halldin MM, Vazquez-Juarez E, Lindskog M, Sandin J, Winblad B, Eriksdotter M, Forsell P (July 2021). "Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction". Cells. 10 (8): 1871. doi:10.3390/cells10081871. PMC 8391421. PMID 34440640.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

This veterinary medicine–related article is a stub. You can help Wikipedia by expanding it.

[1] "Merial Acquires LEGEND® and MARQUIS®". Boehringer Ingelheim. Retrieved 2018-04-30.

[2] "Sanofi and Boehringer Ingelheim confirm Closing of business swap | www.boehringer-ingelheim.com". boehringer-ingelheim.com. Retrieved 2018-04-30.

[3] "Marquis". Drugs.com.

[4] Mackay RJ, Tanhauser ST, Gillis KD, Mayhew IG, Kennedy TJ (March 2008). "Effect of intermittent oral administration of ponazuril on experimental Sarcocystis neurona infection of horses". American Journal of Veterinary Research. 69 (3): 396–402. doi:10.2460/ajvr.69.3.396. PMID 18312139.

[DahlströmMadjidNordvall2021-5] Dahlström M, Madjid N, Nordvall G, Halldin MM, Vazquez-Juarez E, Lindskog M, Sandin J, Winblad B, Eriksdotter M, Forsell P (July 2021). "Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction". Cells. 10 (8): 1871. doi:10.3390/cells10081871. PMC 8391421. PMID 34440640.

[1]

[2]

[3]

[4]

[5]

See also

References